Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications
Open Access
- 15 January 2024
- journal article
- review article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 134 (3) , 333-344
Abstract
Background: A considerable inter‐individual variability has been reported in the relationship between methadone doses applied and serum concentrations achieved in methadone maintenance treatment. However, the underlying causes for this variability are not fully understood.Objectives: We investigated the influence of genetic, pathophysiological and pharmacological factors on serum methadone concentration‐to‐dose ratio (CDR) and discussed the clinical implications of the findings.Methods: We used data from two retrospective laboratory databases and a prospective cohort study to investigate the impact on methadone CDR of hepatic cytochrome P450 enzyme system (CYP) genetic polymorphisms, age, sex, concomitant medication, liver fibrosis and body mass index through linear mixed model analyses.Findings: A positive association was found between CDR and the homozygous CYP2B6*6 genotype, concurrent treatment with CYP3A4 inhibitors and body mass index. CDR was lower among women and during concomitant use of CYP inducers. CDR was not associated with age or the degree of liver fibrosis in our investigations.Conclusions: This research work supports the need for individually tailored dosage considering the various factors that influence methadone CDR. The gained knowledge can contribute to reducing the risks associated with the treatment and optimizing the desired outcomes.Keywords
Funding Information
- Helse Vest Regionalt Helseføretak (F‐11328‐912126, «Åpen prosjektstøtte»)
- Norges Forskningsråd (269855)
This publication has 38 references indexed in Scilit:
- Hepatitis C Virus Infection Influences the S-Methadone Metabolite Plasma ConcentrationPLOS ONE, 2013
- Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceFrontiers in Genetics, 2013
- Contribution of Cytochrome P450 and ABCB1 Genetic Variability on Methadone Pharmacokinetics, Dose Requirements, and ResponsePLOS ONE, 2011
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- Pharmacotherapy in the Treatment of Addiction: MethadoneJournal of Addictive Diseases, 2010
- Role of CYP2B6 in Stereoselective Human Methadone MetabolismAnesthesiology, 2008
- Enantiomeric Metabolic Interactions and Stereoselective Human Methadone MetabolismThe Journal of Pharmacology and Experimental Therapeutics, 2007
- An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and researchJournal of Substance Abuse Treatment, 2005
- Stereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19Chirality, 2003
- Effective Medical Treatment of Opiate AddictionJAMA, 1998